touchONCOLOGY are joined by the EAU Section of Oncological Urology (ESOU) Chairman Professor Morgan Rouprêt to discuss the impact of immune checkpoint inhibitors on the treatment of bladder cancer, and other exciting therapeutic advances.
- How have immune checkpoint inhibitors changed the treatment landscape for bladder cancer? (00:35-03:35)
- What are the most exciting recent and emerging therapeutic advances in bladder cancer? (03:35-05:05)
Speaker Disclosure: Morgan Rouprêt has no conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the EAU Section of Oncological Urology (ESOU) 2022 conference.
Share this Video
Related Videos In Genitourinary Cancer
Highlights in genitourinary cancers (non-prostate) – SunRISe-1, THOR-2, EV-302 CheckMate 901: Petros Grivas, ESMO 2023
ESMO 2023 brought forth some practice-changing data in the field of non-prostate genitourinary cancer. To understand these, as well as the other key trials and highlights from the meeting, we engaged in a conversation with the Clinical Director of the Genitourinary Cancer Program at the University of Washington and Fred Hutchinson Cancer Center, Prof. Petros […]
Top 5 tips for a successful career in medical oncology: Petros Grivas, ESMO 2023
As part the Young Oncologists session, at ESMO 2023, Prof. Petros Grivas (Clinical Director of the Genitourinary Cancer Program, University of Washington and Fred Hutchinson Cancer Center, Seattle, USA) and colleagues, spent time speaking with medial students and early-career physicians about developing a successful career in medial oncology. For those that were unable to attend the […]
ARPi vs. SOC and taxanes in mCRPC – ProBio study: Henrik Grönberg, EMSO 2023
The uniquely designed Prostate Biomarker (ProBio) study (NCT03903835) used outcome-adaptive randomization to compare biomarker-driven treatment selection against physician’s choice, and to compare androgen receptor inhibitors (ARPIs) against standard-of-care (SOC) and taxanes in castrate-resistant prostate cancer (mCRPC). To learn more about the trials unique design, the details surrounding the biomarker signatures investigated and the treatments compared, […]